Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:03:48.406Z.
Calculation as of: 2026-10-06T18:03:48.406Z.
Quote observation: 2026-10-06T17:59:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 270619a8cb927235a94e92f97c71cdfb8fe28fc97d8c39ede642bd89729a24e3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Mobile-health Network Solutions Class A Ordinary Shares
Market Cap
$30263.00
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR) | $30263.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6254.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61088.00 | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70965.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109148.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $243502.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $483178.00 | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
